title: [Clinical comparision of alpha dihydroergocryptine against cabergoline in the treatment of the fibrocystic mastopathy].
abstract: BACKGROUND
  Fibrocystic breast disease is one of the most frequent conditions of the breast among women from 30 to 49 years, with a frequency of about 60%, hence the interest in studying and treating it with the most advanced and effective resources.
  
  
  OBJECTIVE
  To compare the efficacy and adverse events of alpha dihydroergocryptine with cabergoline in patients with fibrocystic breast disease.
  
  
  METHODS
  A prospective, longitudinal, open, comparative study between alpha-dihydroergocryptine and cabergoline, made in the service of Gynecology and Obstetrics at the Dr. Miguel Silva General Hospital in Morelia, Michoacán. 171 patients diagnosed with fibrocystic breast disease were randomly assigned to the alpha-dihydroergocryptine or the cabergoline group. Assessments were made at baseline and every month subsequently. The following symptoms were evaluated: breast tenderness, breast pain, lumps and nipple discharge. The concentrations of prolactin were determined and an ultrasound was performed at baseline and at 3 and 6 months, patients were questioned about adverse events.
  
  
  RESULTS
  171 patients were included (81treated with alpha-dihydroergocryptine and 90 with cabergoline); 156 completed the study. The age limits were 18 and 51 years. The evolution time prior to study entry was 17.71 +/- 18.3 months for the alpha-dihydroergocryptine group and 18.57 +/- 20.35 for the cabergoline group. 15 patients discontinued treatment due to adverse events (8 of the alpha-dihydroergocryptine group and 7 of the cabergoline group). The most common adverse event was headache.
  
  
  CONCLUSIONS
  In this study alpha-dihydroergocryptine was better tolerated and had better clinical response compared with cabergoline; breast pain and breast tenderness disappeared within the first month of treatment. Adverse events were similar for both treatments.
authors: Hospital General Dr. Miguel Silva, Morelia, Michoacán.
authors: Eugenio
authors: E
authors: Castillo-Huerta
authors: Miguel
authors: M
authors: Garibay-Valencia
authors: Felio
authors: F
authors: Mirabent-González
mesh_terms: D000293:Adolescent; D000328:Adult; D000077465:Cabergoline; D025443:Dihydroergocryptine / Q000009:adverse effects / Q000627:therapeutic use*; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005348:Fibrocystic Breast Disease / Q000097:blood / Q000188:drug therapy*; D005687:Galactorrhea / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D059373:Mastodynia / Q000139:chemically induced / Q000209:etiology; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D011446:Prospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004873:Ergolines; D025443:Dihydroergocryptine; D011388:Prolactin; D000077465:Cabergoline